ObjectiveTo compare the long-term economic impact of melanoma prevention by sun protection, with the corresponding impact of early detection of melanoma to decrease melanoma deaths.DesignCost-effectiveness analysis using Markov cohort model. Data were primarily from two population-based randomised controlled trials, epidemiological and costing reports, and included flow-on effects for keratinocyte cancers (previously non-melanoma skin cancers) and actinic keratoses.SettingQueensland, Australia.ParticipantsMen and women with a mean age 50 years modelled for 30 years.InterventionsDaily sunscreen use (prevention) compared with annual clinical skin examinations (early detection) and comparing these in turn with the status quo.Primary and secondary outcomesCosts, counts of melanoma, melanoma deaths, keratinocyte cancers, life years and quality-adjusted life years.ResultsPer 100 000 individuals, for early detection, primary prevention and without intervention, there were 2446, 1364 and 2419 new melanomas, 556, 341 and 567 melanoma deaths, 64 452, 47 682 and 64 659 keratinocyte cancers and £493.5, £386.4 and £406.1 million in economic costs, respectively. There were small differences between prevention and early detection in life years saved (0.09%) and quality-adjusted life years gained (0.10%).ConclusionsCompared with early detection of melanoma, systematic sunscreen use at a population level will prevent substantial numbers of new skin tumours, melanoma deaths and save healthcare costs. Primary prevention through daily use of sunscreen is a priority for investment in the control of melanoma.
Melanoma is a major public health burden in many fair-skinned populations. It is the most serious type of skin cancer and can be fatal if diagnosed at advanced stage. Globally, there are around 60 100 deaths each year from melanoma, with one-quarter of these (around 15 500) occurring in the USA, the UK and Australasia.1 Other skin malignancies such as basal cell carcinoma and squamous cell carcinoma (collectively called keratinocyte cancers (KCs)) are the most common cancers in humans, associated with high costs (US$4.8 billion in the USA in 2011)2 and lowered quality of life though rarely fatal. In addition, benign pigmented skin lesions such as nevi and solar lentigines are very common in fair-skinned individuals while actinic keratoses are common on sun-damaged skin.3 Any evaluation aimed at melanoma control will therefore need to account for the clinical management of these additional skin tumours, malignant and benign, that inevitably will be encountered in the target population.
Ultraviolet (UV) radiation from sunlight or artificial sources is the main environmental cause of melanoma, KCs and actinic keratoses. Primary prevention activities focus on educating the public to protect their skin from UV radiation using protective clothing and sunscreens, rescheduling outdoor activities and reducing use of indoor tanning devices. Evidence of effectiveness is strongest for sunscreen use.4 5 Improving sun protection behaviours requires upfront financial investment in sun safety campaigns and may be difficult in some population segments such as avid tanners and adolescents. Early detection of melanoma saves lives by diagnosing and treating tumours early before they metastasise. There may also be cost benefits in treating small KCs that are detected earlier with treatment by biopsy excision versus more expensive treatment like Mohs surgery. Two large population-based studies have shown that people who had physician skin checks in the 3 years prior to melanoma diagnosis had higher proportions of thin melanomas (≤0.75 mm) than those who had no physician skin checks.6 7 Thickness of melanoma is highly correlated with prognosis8 and so early detection is intuitively appealing and widely supported by dermatologists. However, early detection programmes carry the risk of overdiagnosis and unnecessary treatments because skin examinations increase the yield (and subsequent treatment costs) of indolent skin cancers and benign skin lesions.9 This phenomenon is well documented in screening programmes10 11 where the number of biopsies and excisions of benign skin lesions exceed confirmed skin cancers by fivefold.10 Furthermore, most leading health authorities do not endorse population-wide screening for early melanoma detection because of lack of evidence that screening reduces melanoma mortality.12
Estimating the health and economic value of early detection of melanoma on one hand, and melanoma prevention on the other, are critical for decision-making in settings of constrained health budgets, yet it appears the two strategies have never been compared. We therefore compared the relative cost-effectiveness of programmes of primary prevention of melanoma (through increases in sunscreen use) versus early detection of melanoma (through whole body clinical skin examination) with the status quo, in an Australian population over a 30-year period.
Our study was based on the mainly fair-skinned population of the Australian state of Queensland who experience high UV radiation levels year-round.
Three strategies were compared:
The no intervention strategy represents the general population in Queensland with prevailing levels of sunscreen use and skin examinations (including opportunistic skin checks by family physicians) as reported from the QSKIN Sun and Health Study13 (see online supplementary figure 1). These behaviours are reflected in the costs and outcomes of this modelled strategy. The expected links between strategy and outcomes are illustrated in figure 1. In the absence of long-term skin checking behaviours, we assumed that clinical skin examinations in the early detection scenario remained constant over time and applied equally to men and women over 50. Clinical skin examinations were assumed to be undertaken annually and reflect prevailing clinical competencies and use of dermoscopy. The incidence of new skin cancers remained elevated in the early detection arm with yearly clinical skin examinations as shown over successive years in a 10-year community sample.14 We also assumed that regular sunscreen use remained constant over time, as supported by trial evidence.15 Both the early detection and primary prevention arms represent 100% of individuals receiving skin examinations or using sunscreen, respectively, although their consequent outcomes are based on pragmatic trial evidence where additional background protective behaviours might have occurred.10.1136/bmjopen-2019-034388.supp1
For the primary prevention strategy, we used available data from the community-based Nambour Skin Cancer Prevention Trial (n=1621) that evaluated daily application of sun protection factor (SPF) 15+ sunscreen to face, arms and hands versus discretionary use of sunscreen for skin cancer prevention. Skin cancer outcomes were monitored by dermatological examinations for the first 5 years and then through record linkage to histopathology reports for 15 years.4 5 Trial results showed the effect of daily sunscreen use on incidence of invasive and non-invasive melanomas (HR 0.50, 95% CI 0.24 to 1.02)4 and squamous cell carcinomas (HR 0.65, 95% CI 0.45 to 0.94)5 at 5 years. Routine sunscreen use was sustained in people randomised to the regular application group 12 years after the trial ended.15 The main study limitation is that the results are directly relevant to people living in sunny climates with high ambient sun exposure; however, they will have implications for white people travelling to sunny places for holidays.4
For the early detection strategy, data from the Skin Awareness Trial16 for men over 50 years were used. This scenario modelled the increase in skin examinations in men and women aged over 50 years. The trial randomised 929 male participants selected randomly from the population-based Electoral Roll (enrolment is compulsory) to intervention or control arm.17 The intervention group received comprehensive educational materials about skin self-examination and the importance of consulting the family doctor for lesions of concern.16 The control group received an information brochure only. Histopathology reports of skin cancers and benign lesions were obtained at 12 months only.16 We estimated long-term survival using population data of melanoma thickness.6 Trial results showed increased skin self-examinations in the intervention group (35.3%) versus in the control group (27.2%).16 For lesions that were managed by physicians, there was a higher proportion of malignant lesions in the intervention group (60%) versus in the control group40%.16 The key limitation of this study is that men were relatively more skin aware at baseline (no differences between randomised arms) and not all participants gave permission for the researchers to contact their physicians 321/540 (59.4%).16
A Markov health state transition cohort model was constructed in TreeAge Pro for Healthcare 2019 (TreeAge Software, Williamstown, Massachusetts, USA) (figure 2). The model prospectively tracked the expected consequences of occurrences and sequelae of new skin lesions. The health states included: (1) melanoma (in situ; ‘thin’ (≤1 mm thickness); ‘thicker’ (>1 mm); (2) undetected melanoma; (3) KCs; (4) undetected KCs; (5) benign skin lesions; (6) undetected benign lesions; (7) lesion-free and (8) postdiagnosis, thin melanoma; (9) postdiagnosis, thicker melanoma; (10) melanoma deaths and (11) other deaths. Melanomas were categorised into ≤1 mm and >1 mm Breslow thickness to enable a parsimonious model structure but weighted values for survival and costs reflect the specific stage differences. The model had annual cycles and the cohort could move between health states when they faced different probabilities of developing skin cancers or skin lesions or they could remain in the same state (eg, lesion-free). Some people developed multiple skin cancers and benign lesions and risk increased with age. Despite the competing risks of different skin cancers, coherence was maintained with probabilities totalling less than 1.0 in the model branches. The model tracked the cohort (mean age 50 years (SD 9)) from inception through the next 30 years. Death from melanoma18 including from advanced melanoma,19 another skin cancer or other causes20 could occur at any time.
Model inputs and sources are provided in table 1 and the online supplementary file with more detailed information on calculations (eg, weighted means, rate to probability conversions) and background data. Briefly, from the Nambour trial, we estimated the effect of daily sunscreen use on incidence of invasive and non-invasive melanomas (HR 0.50, 95% CI 0.24 to 1.02)4 and squamous cell carcinomas (HR 0.65, 95% CI 0.45 to 0.94)5 (latter used for ‘KCs’ health state). We estimated long-term survival using population data of melanoma thickness.6 Undetected skin tumours were estimated from a pilot melanoma screening trial in Queensland involving 16 383 skin examinations and showed numbers of suspicious lesions that were histopathologically confirmed as skin tumours (23% melanoma, 14% KCs and 40% benign tumours).21
|Base model values||Values in one-way sensitivity analyses||Parameters for probabilistic sensitivity analyses*||Sources|
|Base estimate||Low estimate||High estimate||Distribution type and values|
|Duration of the model||30 years||10 years||40 years||n/a||n/a|
|Starting age of cohort||50 years||30||60||Normal (mean 50, SD 9)||n/a|
|Person developing benign lesions||0.3832||0.2911||0.4753||Beta (n=107, r=41)†||Janda et al, Control group16|
|Person developing multiple benign lesions||0.5064||0.428||0.5849||Darlington et al 24, Streeton et al 31|
|Person developing keratinocyte cancers||Age-dependent table||–||–||Table (see online supplementary file), for example, 39 years=0.0180, 79 years=0.0709||Pandeya et al 22|
|Person developing multiple keratinocyte cancers||Age-dependent table||–||–||Pandeya et al 22|
|Person developing melanoma||Age-dependent table||–||–||Table (see online supplementary file), for example, age 44 years=0.0006, 79 years=0.0029||Qld Cancer Statistics On-Line (av 2011–2015)18|
|Person developing multiple melanomas||0.007||0.006||0.009||–||Youlden et al 26|
|Those with melanoma have an invasive thin melanoma in general population (0<1 mm)||0.282||0.26||0.30||Beta (n=97 114, r=27 386)†||Aitken et al 23 (remainder of thick and thin have in situ)|
|Those with melanoma have thicker melanoma in general population (>1 mm)||0.27||0.25||0.29||Beta (n=97 114, r=26 221)†||Aitken et al 23|
|Those with melanoma have thicker melanoma (>1 mm) with whole body clinical skin examination (early detection)||0.25||0.21||0.29||Beta (n=97 114, r=24 747)†||18% reduction in thick melanoma over 3 years Aitken et al ,23 applied to Aitken et al 6|
|Undetected melanomas||0.231||–||–||Beta (α=33.94, β=112.93)||Aitken et al 21|
|Undetected KCs||0.138||–||–||Beta (α=38.17, β=238.39)||Aitken et al 21|
|Undetected benign lesions||0.395||–||–||Beta (α=26.49, β=40.57)||Aitken et al 21|
|Undetected tumour being detected||0.20||0.15||0.25||Beta (α=35.36, β=141.42)||Assumption|
|Death from melanoma if ≤1 mm (thin) by age||5 year=0.02|
|–||–||–||Weighted by tumour size categories, Gershenwald et al 8 (see online supplementary file)|
|Death from melanoma if >1 mm (thicker)||5 year=0.233|
|Mortality in Queensland general population||Age-dependent table||–||–||–||Australian Bureau of Statistics, Life tables, 2015–2017, Qld population, Table 1.920|
|Rate ratio for KCs and melanomas found during early detection||1.50||1.40||1.60||Gamma (α=44.4, λ=29.63)||Janda (2014), 60% skin malignancies versus 40% in control—so 50% increase in skin cancers found16|
|Rate ratio of melanoma in sunscreen users||0.50||0.45||0.55||Beta (α=312, β=312)||Green et al , invasive and non-invasive melanomas4|
|Rate ratio of KCs in daily sunscreen users||0.65||0.45||0.94||Beta (α=14.91, β=8.03)||Van der Pols et al , 1993–2004 follow-up, persons affected, applied rate for squamous cell carcinomas5|
|Rate reduction of benign lesions in daily sunscreen users||0.76||0.66||0.86||Beta (α=9.91, β=3.13)||Darlington et al ,24 24% rate reduction in actinic keratoses|
|Rate of undetected skin tumours being detected annually||0.20||0.15||0.25||Beta (α=35.36, β=141.42)||Assumption|
|Health utilities (quality of life)|
|Benign lesions and being lesion free||1.00||–||–||–||Assumption|
|Having keratinocyte cancers||0.98||0.95||0.99||Beta (α=5.21, β=0.09)||Seidler et al 30|
|Disutility of each subsequent KC or benign lesion treated||−0.03||−0.04||−0.02||–||Seidler et al 30 used disutility for KC recurrence|
|In situ or thin melanoma (≤1 mm)||0.97||0.9||0.98||Beta (α=0.28, β=0.009)||Tran et al 28 meta-analysis|
|Thicker melanoma (>1 mm)||0.77||0.7||0.83||Beta (α=5.29, β=1.58)||Tran et al 28 meta-analysis|
|Sunscreen in high users (per year)||13.5||9.5||17.6||Gamma (α=44.4, λ=2.28)||Retail supermarket brand, 50+SPF sunscreen 500 mL @AU$6.50 each, 3 bottles each year|
|Sunscreen in low users (per year)||4.5||3.2||5.9||Gamma (α=44.4, λ=6.84)||As above, 1 bottle used every 3 years|
|Clinical whole body skin examination—higher use in early detection||78.33||38.59||117.50||Gamma (α=44.4, λ=2.28)||Standard GP consultation, MBS item 23 plus patient out of pocket fees|
|Clinical whole body skin examination—lower use in primary prevention and no intervention||13.06||0||39.17||Gamma (α=44.4, λ=6.84)||As above, 1 per 3 years|
|Diagnose and treat a benign lesion||115.5||80.8||150.1||Gamma (α=44.4, λ=0.42)||Streeton 2006 for treatment types and Medicare items|
|Treating first KC||218.9||186.1||251.1||Gamma (α=44.4, λ=0.14)||Gordon et al ,25 mean cost|
|Treating multiple KCs||414.0||351.9||476.1||Gamma (α=44.4, λ=0.08)||Gordon et al ,25 mean cost|
|Thick melanoma in first year||22 607.0||16 524.9||30 689.1||Gamma (α=44.4, λ=0.001)||Elliott et al 46 Weighted by tumour size|
|Thick melanoma after year 1||Time dependent table||–||Elliott et al ,46 AU$7262 for 2 years weighted by tumour size, AU$1275 thereafter|
|In situ and thin melanoma in first year||1189.5||832.7||1546.4||Gamma (α=44.4, λ=0.03)||Elliott et al 46|
|In situ and thin melanoma after year 1||115.5||0.0||0.0||–||Elliott et al ,46 constant cost of follow-up|
|Care for person in last months of life||16 591.1||11 613.8||21 568.5||–||Reeve et al 47 (death from other causes)|
|Death from thicker melanoma (>1 mm)||23 662.8||16 563.9||30 761.6||–||Reeve et al 47 (death from cancer)|
|Premature death from melanoma—productivity losses||207 794.6||176 625.4||238 963.8||–||Carter et al 17 (applies to persons aged <65 years)|
Transition probabilities unrelated to interventions . In each annual cycle, a proportion of people will either continue to live without skin cancer or develop melanoma, KC or other skin lesions. The risks of developing skin cancer increase with age. Incidence of KCs was based on the QSKIN study and observed excisions of at least one KC during 2011–2014 by age-group.22 Once treated, individuals can develop subsequent skin cancers, other skin lesions or remain ‘lesion-free’. Based on data from the Queensland Cancer Registry from 1995 to 2014,23 the proportions of in situ (45%), thin ≤1 mm melanomas (28%%) and thicker >1 mm melanomas (27%) were applied in the model. Probabilities for subsequent multiple skin lesions and tumours were based on Queensland studies.22 24–26 Incidence of multiple invasive melanomas was available from Youlden et al .26 For subsequent melanomas, the thickness distribution (and associated mortality) of melanomas for individuals with multiple melanomas was the same for singular melanomas.27 Mortality rates for thin melanomas were extracted from the latest survival data from melanoma from worldwide data (n>46 000).8 Health utility scores for melanoma stages, including patients with advanced melanoma receiving targeted therapies, were obtained from a meta-analysis (table 1).28 Robust evidence on health utilities for patients with KC or benign skin lesions is limited, but there is an appreciable quality of life effect where some individuals face disfiguring, multiple cancers, anxiety and other symptoms.29 From Seidler et al , we assigned a utility score of 0.984 to patients with KCs (0.95 and 0.99 in sensitivity analysis) and a utility reduction of −0.03 each time an individual had an additional KC.30
The study took a societal perspective and included health provider resources, consumer expenses for sunscreen and copayments for medical treatments and productivity losses to society for each premature melanoma death.17 We included the costs of a primary prevention campaign at AU$0.35 per capita which was conservatively twice that of recent funding for a skin awareness campaign awarded in Western Australia. Healthcare costs included family physician visits for skin checks, specialist visits, pathology and treatments for melanomas, KCs and benign lesions (ie, cryotherapy, excision, topical creams).31 Resources were valued using those reported in the literature or national price schedules, inflated to 2018 Australian dollars and converted into UK pounds (AUD1.444=US$1.0=£0.713 using purchasing power parities).
The main outcomes of interest were counts of melanomas (in situ, thin ≤1 mm and thicker >1 mm), melanoma deaths, KC counts, healthcare costs, survival (life years) and quality-adjusted life years (QALYs). Mean costs, QALYs and all other outcomes for the three strategies were calculated with Monte Carlo simulation analysis and presented per 100 000 persons. Future costs and QALYs were discounted at 3% per year to provide present values. We calculated incremental cost-effectiveness ratios to compare the strategies: the difference in mean costs for two strategies divided by the difference in mean QALYs. Probability distributions for each parameter were assigned using the 95% CIs (if available) or ±15% of the base value (table 1). We conducted one-way sensitivity analyses in which each model input was varied between high and low values (online supplementary figure 2). Scenarios were performed for different durations (10–50 years), starting ages (30–60 years) and removing discounting. Results of the base case probabilistic sensitivity analysis using Monte Carlo simulation and 5000 iterations at random were presented in an incremental cost-effectiveness scatterplot. As a benchmark for cost-effective healthcare in Australia,32 a threshold of AU$50 000 per QALY gained was used. We validated the model by running internal coherence checks, checked all inputs with two modellers and assessed predicted outcomes with external reports. Best-practice guidelines for health economic modelling33 34 were adhered to.
For the next 30 years where no intervention occurs, it was predicted that for every 100 000 persons, 2419 melanomas, 567 melanoma deaths and 64 659 KCs will occur (table 2). Furthermore, 2.6 million life years, 1.8 million QALYs and £406.1 million in economic costs were predicted (table 2). This compares with the 30-year outcomes of a primary prevention strategy of 1055 fewer melanomas, 226 fewer melanoma deaths, 16 977 fewer KCs, 1736 additional QALYs and £19.7 million savings in societal costs (table 2). Conversely, for the early detection strategy compared with no intervention, there would be an estimated 21 melanomas (previously undetected), 793 additional KCs, 6 fewer QALYs and cost an additional £87.4 million (table 2). With early detection, diagnosing melanomas that were previously undetected is a positive finding leading to lower-risk cancers but health utility decrements accrue for all melanomas and KCs and the higher numbers of early stage cancers and KCs for resulted in slightly fewer overall QALYs than the no intervention strategy. Primary prevention was superior to early detection across most outcomes but at the expense of 21 undetected melanomas per 100 000 and produced small differences in life years (0.09%) and QALYs (0.10%) (table 2, online supplementary figures 3–5). Compared with primary prevention, early detection cost an additional £107.1 million (22%) to society, and there were 531 (47%) more in situ melanomas, 311 (45%) more thin melanomas and 261 (42%) more thicker melanomas per 100 000 persons (table 2).
|Early detection||Primary prevention||No intvn||Primary versus ED difference||ED versus no intvn difference||Primary versus no intvn difference|
|Number of melanomas|
|In situ melanomas*||1133||601||1074||−531||59||−473|
|Thin melanomas (0≤1 mm)*||690||379||676||−311||14||−298|
|Thick melanomas (>1 mm)*||623||362||647||−261||−24||−285|
|Number of deaths from melanoma*||556||341||567||−215||−11||−226|
|Number of excised keratinocyte cancers*||65 452||47 682||64 659||−17 770||793||−16 977|
|Societal costs (£million)||£493.5||£386.4||£406.1||−£107.1||£87.4||−£19.7|
|QALYs||1 821 195||1 822 937||1 821 201||1742||−6||1736|
|Life years*||2 635 444||2 637 734||2 635 396||2290||49||2338|
Regarding incremental cost per QALY ratios, one-way sensitivity analyses showed the most important model inputs were unit cost of skin examinations (range £27.52–£83.78); probability of a melanoma being >1 mm (0.21–0.29); rate reduction of benign lesions (0.66–0.86) and health utility of KCs (0.95–0.99) (table 3). These variables changed the ‘base-case’ incremental cost per QALY ratio for primary prevention versus early detection between −£185 000 and −£31 000 but the overall finding that primary prevention incurred lower costs but higher QALYs than early detection remained unchanged. If the mortality probability of thick melanoma (>1 mm) at 5 years (0.233) and 10 years (0.301) was lowered to 0.19 and 0.26, respectively, effect was small and more in favour of primary prevention (4% improvement) (table 3).
|Costs (£ millions)||Quality-adjusted life years||Primary prevention versus early detection||Primary prevention versus no intvn|
|Early detection||Primary prevention||No intvn||Early detection||Primary prevention||No intvn||Incremental cost (£m)||Incremental QALYs||Incremental cost (£m)||Incremental QALYs|
|Base case (30 years duration, age 50, 3% discounting costs and QALYs)||493.5||386.4||406.1||1 821 195||1 822 937||1 821 201||−107.1||1742||−19.7||1736|
|Cost of wbCSE in high users(base AU$112.80)|
|Cost of wbCSE in high users=$55.58||441.3||386.4||406.1||1 821 195||1 822 937||1 821 201||−54.9||1742||−19.7||1736|
|Cost of wbCSE in high users=$169.20||545.4||386.4||406.1||1 821 195||1 822 937||1 821 201||−159.0||1742||−19.7||1736|
|Prob thick melanoma (base 0.25)|
|Prob thick melanoma=0.21||488.2||386.4||406.1||1 821 686||1 822 937||1 821 201||−101.8||1251||−19.7||1736|
|Prob thick melanoma=0.29||497.7||386.4||406.1||1 820 811||1 822 937||1 821 201||−111.3||2126||−19.7||1736|
|Rate reduction in benign lesions from sunscreen (base 0.76)|
|RR 0.66||493.5||381.1||406.1||1 821 195||1 822 822||1 821 201||−112.4||1627||−25.1||1621|
|RR 0.86||493.5||392.1||406.1||1 821 195||1 823 055||1 821 201||−101.5||1860||−14.0||1854|
|KC utility (base 0.98)|
|Utility 0.95||493.5||386.4||406.1||1 819 784||1 821 928||1 819 831||−107.1||2145||−19.8||2097|
|Utility 0.99||493.5||386.4||406.1||1 821 408||1 823 086||1 821 408||−107.1||1677||−19.8||1677|
|Rate reduction in melanoma from sunscreen (base 0.50)|
|RR 0.45||493.5||384.2||406.1||1 821 195||1 823 158||1 821 201||−109.3||1963||−21.9||1957|
|RR 0.55||493.5||388.5||406.1||1 821 195||1 822 720||1 821 201||−105.0||1525||−17.6||1519|
|Mortality prob of thick—5 years:0.233;10 years:0.301|
|Prob 0.27 to 0.34||494.3||386.8||407.0||1 821 065||1 822 867||1 821 069||−107.5||1802||20.1||1799|
|Prob 0.19 to 0.26||492.4||385.8||405.0||1 821 376||1 823 035||1 821 387||−106.6||1659||19.2||1648|
When the model duration was shortened to 10 years, or separately increased to 40 years, incremental cost savings (per 100 000) for primary prevention versus early detection were £52.9 million and £116.5 million, respectively (table 4). Reducing the starting age to 30 years and raising it to 60 years produced cost savings of £112.0 million and £93.1 million, respectively, and discounting or not, also produced large differences in costs and QALYs (table 4). The probability that primary prevention was cost effective compared with early detection was 100% (online supplementary figures 3-5). Per person mean incremental cost savings for primary prevention versus early detection were £1071 (95% credible interval: £679 to £1490) and mean QALYs were 0.0174 (95% credible interval: 0.0069 to 0.0365). Model validation indicated high external validity (online supplementary file).
|Costs (£ millions)||QALYs||Primary prevention versus early detection||Primary prevention versus no intvn|
|Early detection||Primary prevention||No intvn||Early detection||Primary prevention||No intvn||Incremental cost (£m)||Incremental QALYs||Incremental cost (£m)||Incremental QALYs|
|Base case (30 years duration, age 50, 3% discounting costs & QALYs)||493.5||386.4||406.1||1 821 195||1 822 937||1 821 201||−107.1||1742||−19.7||1736|
|Duration of model|
|10 years||166.5||113.6||121.3||860 698||860 985||860 726||−52.9||287||−7.7||259|
|20 years||327.5||240.5||256.0||1 453 667||1 454 612||1 453 701||−87.0||945||−15.5||910|
|40 years||639.4||522.9||544.3||2 003 133||2 005 477||2 003 101||−116.5||2344||−21.4||2376|
|Starting age (mean of distribution)|
|30 years||306.7||194.6||211.9||1 978 959||1 979 806||1 978 953||−112.0||848||−17.3||854|
|40 years||370.5||257.2||278.0||1 933 075||1 934 407||1 933 072||−113.3||1332||−20.8||1335|
|60 years||674.1||581.0||596.8||1 603 495||1 605 381||1 603 524||−93.1||1886||−15.8||1857|
|Costs 3%, QALYs 0%||493.5||386.4||406.1||2 633 348||2 636 361||2 633 329||−107.1||3013||−19.7||3031|
|Costs 0%, QALYs 0%||786.6||631.0||659.9||2 633 348||2 636 361||2 633 329||−155.7||3013||−28.9||3031|
In mid-aged people followed up for 30 years, systematic improvements in sunscreen use would prevent skin cancers and benign skin tumours and bring significant cost savings. Melanoma deaths after 30 years of regular sunscreen use would be one-third less of that after 30 years of increased clinical skin examinations. As expected with an early detection intervention, higher numbers of detected melanomas, KCs and all other skin lesions would be diagnosed and treated than with either the primary prevention or the no intervention scenario. Early detection was favourable in detecting early stage, treatable skin cancers; however, these higher proportions of thin melanomas presenting for medical attention did not offset the economic and quality of life burdens incurred by concurrently detecting higher numbers of KCs and benign skin lesions. Conversely, primary prevention has the dual benefits by avoiding skin cancers altogether and reducing quality of life decrements and costs relative to early detection, although some melanomas would be undetected. With the majority of melanomas routinely detected at early stages in the general population without dedicated surveillance, there is minimal impact on mortality (and therefore life years).
We compared primary prevention with early detection and a ‘no intervention’ baseline group but it is important to stress that the interventions were based on pragmatic trials that meant individuals could engage in their normal skin behaviours in Queensland. In earlier iterations of the model, we considered alternative behavioural scenarios but chose the current status quo (or mixed behavioural scenario reflecting real-life) with alternative best possible strategies. Although it may be unrealistic to achieve 100% compliance with protective behaviours, within a pragmatic trial with multiple behaviours possible, the strategies more correctly align with the data inputs on outcomes after these behaviours. Behaviours were not explicitly modelled but rather their consequences through rate ratios of skin cancers or thick melanomas and costs. Our use of distributions around the key estimates in the probabilistic sensitivity analyses will implicitly cover the variations in skin behaviours, costs and health-related quality of life. For example, decrements in quality of life associated with being diagnosed with a skin cancer is likely to be directly related to both treatment and psychological concerns but varies from person to person.
Eight previous economic evaluations of melanoma early detection programmes have been reported: three Australian,35 three US35 and one Belgian36 and UK.37 All studies used long-term Markov or decision-analytic models as we did, and all showed early detection producing a downshift of melanoma stage and improved survival.35 Several studies included the costs for increased case-finding of KCs and benign tumours but only recent studies recognised the importance of quality of life and used QALYs as a primary outcome.36 38 39 Economic evaluations of primary prevention of skin cancer have varied in intervention type and duration but all have shown favourable economic and health benefits.35
In our ageing populations, mortality from melanoma competes with all-cause mortality. At a population level, the deaths of a small proportion (~5%) of people with melanoma that have advanced melanoma are somewhat diluted by deaths from other common diseases and so the gains in life years from population health strategies are elusive. Instead of population screening, screening those at known high risk of melanoma based, for example, on high numbers of nevi, or fair skin type, has been proposed.39 Developments in imaging technologies may bring improved diagnostic accuracy given that a proportion of difficult-to-diagnose melanomas and KCs40 are liable to misdiagnosis.
We have previously shown that primary prevention via regular sunscreen use reduces economic burden.41 In England, it is estimated that £180 million will be spent by the NHS on skin cancer by 2020.42 In the USA, the annual economic burden of treating melanoma and KCs is US$8.1 billion, increasing each year.2 Between 2002–2006 and 2007–2011, growth in costs of melanoma and KCs alone was fivefold higher than for all other cancers and would be even higher if the full cost of treated benign skin tumours were also counted. For example, over 35.6 million actinic keratoses were treated in the US Medicare population in 2015, increasing from 29.7 million in 2007.43 Consequently, the scope for future cost savings to health economies through investment in skin cancer campaigns is considerable.35
The generalisability of these findings will be limited to settings resembling this study’s, although the expected relativities of cost, intervention and quality of life effects should be proportional to country-specific skin cancer incidence. Some assumptions were necessary in our models, particularly regarding melanoma mortality rates in the early detection arm, since to date no relevant trials have been adequately powered to detect melanoma deaths. Reports of melanoma mortality after population screening for melanoma in Germany have been mixed.44 A further issue is the optimal frequency of skin checks since even annual checks may miss rapidly-growing nodular melanomas at a curable stage. For health utilities of multiple KCs and benign skin tumours where data are scarce, we used proxies and small disutility values for these events. We relied on self-reports of skin checks and sunscreen use from the QSKIN study and cannot rule out responder bias. Similarly, self-reported skin checks after melanoma diagnosis in a case control study6 may have been prone to recall bias and random misclassification, though the association between physician skin checks and thinner melanomas has been reported by others.7 Clinical skin examination frequency and outcomes were based on Janda et al ’s 13-month follow-up data but may vary in practice and therefore produce different numbers of skin malignancies in the early detection arm.16 Although the Nambour trial used SPF15+ sunscreen and our estimates may be conservative compared with sunscreen SPF30+, the effects of the very small difference in per cent UV filtered by SPF15+ vs 30+ sunscreens45 would have been covered by our sensitivity analyses. Similarly, categorising thin melanomas as <0.8 mm8 rather than ≤1 mm, would not have changed relative differences observed across strategies. Finally, no indirect comparison analysis was undertaken between the randomised trials by Green et al 4 and Janda et al. 16 At baseline, study participants had similar proportions with fair skin (56% in Green vs 62% in Janda) and sunscreen use (35% in Green vs 33% in Janda). However, Green and Janda study participants differed by age (included 20–69 year olds vs over 50 year olds), gender (men 43% vs 100%) and previous history of skin cancers (25% vs 71%), respectively.
These limitations should be set against the major strengths of this work, namely that we used data from two randomised controlled trials, thus minimising internal bias. We also relied on epidemiological and economic studies in the same general population, with the same ambient UV radiation levels and the same health system. We used melanoma diagnosis and mortality data from the Queensland Cancer Registry that is considered highly accurate and complete.
We have shown that primary prevention through daily use of sunscreen emerges as the priority for investment in the control of melanoma, and secondarily of KC and actinic keratoses in high-risk populations like Queensland’s. As a corollary, there would be no long-term economic benefit in moving to implement whole body clinical skin examinations of people aged over 50 years to reduce the impact of melanoma. Further research is required to assess relative cost-benefit of early detection of melanoma in high risk subgroups versus prevention.
We gratefully thank Professor Andrew Searles from Hunter Medical Research Institute who reviewed an earlier draft of the manuscript.